Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events

VANCOUVER, Dec. 24, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has received a Complete Response Letter...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news